表紙
市場調査レポート

膵内分泌腫瘍 - パイプライン製品の分析

Pancreatic Endocrine Tumor - Pipeline Review, H2 2015

発行 Global Markets Direct 商品コード 321926
出版日 ページ情報 英文 49 Pages
即納可能
価格
本日の銀行送金レート: 1USD=106.12円で換算しております。
Back to Top
膵内分泌腫瘍 - パイプライン製品の分析 Pancreatic Endocrine Tumor - Pipeline Review, H2 2015
出版日: 2015年11月25日 ページ情報: 英文 49 Pages
概要

膵内分泌腫瘍は膵神経内分泌腫瘍(PNETs)とも呼ばれる進行の緩徐な希少がんです。症状は持続的な胃痛、ひどい胸やけや下痢、脂肪便、胃出血、嘔吐、体重減少などです。

当レポートでは、膵内分泌腫瘍に対する治療薬の開発状況について調査分析し、パイプライン製品の概要、治験の段階別の製品の概要、主要企業プロファイル、薬剤のプロファイル、パイプライン製品の最新動向、最新ニュースとプレスリリースなどについて、体系的な情報を提供しています。

目次

イントロダクション

膵内分泌腫瘍の概要

治療薬の開発

  • パイプライン製品:概要
  • パイプライン製品:比較分析

開発中の治療薬:企業別

パイプライン製品の概要

  • 後期段階の製品
  • 臨床段階の製品
  • 初期段階の製品

開発中の製品:企業別

治療薬の開発に従事している企業

  • Ipsen S.A.
  • Jiangsu Hengrui Medicine Co., Ltd.
  • MediaPharma s.r.l.
  • Novartis AG
  • OXiGENE, Inc.

治療薬の評価

  • 単独療法の製品
  • 標的別
  • 作用機序別
  • 投与経路別
  • 分子タイプ別

薬剤のプロファイル

  • buparlisib hydrochloride
  • dovitinib lactate
  • fosbretabulin tromethamine
  • lanreotide acetate
  • MPHE-001B
  • SHR-1020
  • X-82

最新のパイプライン情報

開発が中止された製品

製品開発のマイルストーン

  • 注目のニュースとプレスリリース

付録

図表

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: GMDHC7397IDB

Summary

Global Markets Direct's, 'Pancreatic Endocrine Tumor - Pipeline Review, H2 2015', provides an overview of the Pancreatic Endocrine Tumor's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Pancreatic Endocrine Tumor, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Pancreatic Endocrine Tumor and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Pancreatic Endocrine Tumor
  • The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in the therapeutics development for Pancreatic Endocrine Tumor and enlists all their major and minor projects
  • The report summarizes all the dormant and discontinued pipeline projects
  • A review of the Pancreatic Endocrine Tumor products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • A detailed assessment of monotherapy and combination therapy pipeline projects
  • Coverage of the Pancreatic Endocrine Tumor pipeline on the basis of target, MoA, route of administration and molecule type
  • Latest news and deals relating related to pipeline products

Reasons to buy

  • Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Identify and understand important and diverse types of therapeutics under development for Pancreatic Endocrine Tumor
  • Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
  • Devise corrective measures for pipeline projects by understanding Pancreatic Endocrine Tumor pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Pancreatic Endocrine Tumor Overview
  • Therapeutics Development
    • Pipeline Products for Pancreatic Endocrine Tumor - Overview
    • Pipeline Products for Pancreatic Endocrine Tumor - Comparative Analysis
  • Pancreatic Endocrine Tumor - Therapeutics under Development by Companies
  • Pancreatic Endocrine Tumor - Pipeline Products Glance
    • Late Stage Products
    • Clinical Stage Products
    • Early Stage Products
  • Pancreatic Endocrine Tumor - Products under Development by Companies
  • Pancreatic Endocrine Tumor - Companies Involved in Therapeutics Development
    • Ipsen S.A.
    • Jiangsu Hengrui Medicine Co., Ltd.
    • MediaPharma s.r.l.
    • Novartis AG
    • Tyrogenex, Inc.
  • Pancreatic Endocrine Tumor - Therapeutics Assessment
    • Assessment by Monotherapy Products
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Drug Profiles
    • lanreotide acetate - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • MPHE-001B - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • pasireotide LAR - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • SHR-1020 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • X-82 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
  • Pancreatic Endocrine Tumor - Recent Pipeline Updates
  • Pancreatic Endocrine Tumor - Discontinued Products
  • Pancreatic Endocrine Tumor - Product Development Milestones
    • Featured News & Press Releases
      • Oct 15, 2015: Ipsen Announces Eight Studies of Somatuline Depot (lanreotide) in Gastroenteropancreatic Neuroendocrine Tumors Being Presented at the North American Neuroendocrine Tumor Society Symposium
      • Oct 06, 2015: Health Canada Approves Somatuline Autogel (lanreotide) Injection for the treatment of enteropancreatic neuroendocrine tumours
      • May 14, 2015: Ipsen Announces Data Presentations for Somatuline Depot (lanreotide) in Gastroenteropancreatic Neuroendocrine Tumors at American Society of Clinical Oncology Annual Meeting
      • Apr 14, 2015: MHRA approves Ipsen's Somatuline (lanreotide) Autogel 120mg as a new treatment for gastroenteropancreatic tumours
      • Jan 13, 2015: Ipsen Biopharmaceuticals to Present Further Data on Recently FDA-Approved Antitumor Therapy, Somatuline Depot (lanreotide), at Gastrointestinal Cancers Symposium
      • Dec 16, 2014: Ipsen's Somatuline Depot is the first therapy approved by the FDA in the United States for the treatment of patients with locally advanced or metastatic gastroenteropancreatic neuroendocrine tumors
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for Pancreatic Endocrine Tumor, H2 2015
  • Number of Products under Development for Pancreatic Endocrine Tumor - Comparative Analysis, H2 2015
  • Number of Products under Development by Companies, H2 2015
  • Comparative Analysis by Late Stage Development, H2 2015
  • Comparative Analysis by Clinical Stage Development, H2 2015
  • Comparative Analysis by Early Stage Development, H2 2015
  • Products under Development by Companies, H2 2015
  • Pancreatic Endocrine Tumor - Pipeline by Ipsen S.A., H2 2015
  • Pancreatic Endocrine Tumor - Pipeline by Jiangsu Hengrui Medicine Co., Ltd., H2 2015
  • Pancreatic Endocrine Tumor - Pipeline by MediaPharma s.r.l., H2 2015
  • Pancreatic Endocrine Tumor - Pipeline by Novartis AG, H2 2015
  • Pancreatic Endocrine Tumor - Pipeline by Tyrogenex, Inc., H2 2015
  • Assessment by Monotherapy Products, H2 2015
  • Number of Products by Stage and Target, H2 2015
  • Number of Products by Stage and Mechanism of Action, H2 2015
  • Number of Products by Stage and Route of Administration, H2 2015
  • Number of Products by Stage and Molecule Type, H2 2015
  • Pancreatic Endocrine Tumor Therapeutics - Recent Pipeline Updates, H2 2015
  • Pancreatic Endocrine Tumor - Discontinued Products, H2 2015

List of Figures

  • Number of Products under Development for Pancreatic Endocrine Tumor, H2 2015
  • Number of Products under Development for Pancreatic Endocrine Tumor - Comparative Analysis, H2 2015
  • Number of Products under Development by Companies, H2 2015
  • Comparative Analysis by Clinical Stage Development, H2 2015
  • Assessment by Monotherapy Products, H2 2015
  • Number of Products by Top 10 Targets, H2 2015
  • Number of Products by Stage and Top 10 Targets, H2 2015
  • Number of Products by Top 10 Mechanism of Actions, H2 2015
  • Number of Products by Stage and Top 10 Mechanism of Actions, H2 2015
  • Number of Products by Top 10 Routes of Administration, H2 2015
  • Number of Products by Stage and Top 10 Routes of Administration, H2 2015
  • Number of Products by Top 10 Molecule Types, H2 2015
  • Number of Products by Stage and Top 10 Molecule Types, H2 2015
Back to Top